Literature DB >> 30879094

Implementation of an intensified outpatient follow-up protocol improves outcomes in patients with ventricular assist devices.

Sonja Hamed1, Bastian Schmack2, Florian Mueller1,2, Philipp Ehlermann1, Davina Hittmann1, Arjang Ruhparwar2,3, Hugo A Katus1,2, Philip W Raake1,3, Michael M Kreusser4,5.   

Abstract

BACKGROUND: Ventricular assist devices (VAD) are increasingly used as long-term treatment for advanced heart failure. However, survival after VAD implantation is still unsatisfactory, and no specific outpatient follow-up algorithms have been formally established. Here, we evaluate the effect of an intensified follow-up protocol (IFUP) on survival rates and VAD-associated complications. METHODS AND
RESULTS: This is a retrospective study of 57 patients who received a VAD at our center between February 2013 and December 2017. Inclusion criteria were discharge home after VAD implantation and follow-up in our VAD outpatient clinic. Patients implanted after October 2015 (n = 30) were monitored according to IFUP. This protocol embodied formalized, multi-disciplinary clinical visits every 4-8 weeks including a cardiologist, a cardiothoracic surgeon and a VAD-coordinator and was characterized by optimized anticoagulation and wound management as well as guideline-directed medical therapy. One-year survival in the IFUP patients was 97%, compared to 74% in the pre-IFUP era (p = 0.01). Implementation of IFUP was associated with a 90% risk-reduction for 1-year mortality (relative risk 0.099; p = 0.048). The rate of complications, e.g., device thrombosis and major bleeding, was significantly reduced, resulting in superior event-free survival in the IFUP group (p = 0.003). Furthermore, by implementation of IFUP, a more stable anticoagulation adjustment was achieved as well as an improved adherence to guideline-directed medical therapy.
CONCLUSION: Implementation of an IFUP for VAD patients is associated with a significant decrease in 1-year all-cause mortality. This emphasizes the need for more vigilance in the management of VAD patients by a dedicated multi-disciplinary team.

Entities:  

Keywords:  Advanced heart failure; Follow-up protocol; Mechanical circulatory support; Outpatient care; Ventricular assist devices

Mesh:

Year:  2019        PMID: 30879094     DOI: 10.1007/s00392-019-01451-9

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  40 in total

1.  Long-term use of a left ventricular assist device for end-stage heart failure.

Authors:  E A Rose; A C Gelijns; A J Moskowitz; D F Heitjan; L W Stevenson; W Dembitsky; J W Long; D D Ascheim; A R Tierney; R G Levitan; J T Watson; P Meier; N S Ronan; P A Shapiro; R M Lazar; L W Miller; L Gupta; O H Frazier; P Desvigne-Nickens; M C Oz; V L Poirier
Journal:  N Engl J Med       Date:  2001-11-15       Impact factor: 91.245

2.  Extempore interventional closure of a broken CircuLite Synergy micropump inflow graft defect.

Authors:  Bastian Schmack; Matthias Gorenflo; Fabian Rengier; Arjang Ruhparwar
Journal:  J Heart Lung Transplant       Date:  2013-08-08       Impact factor: 10.247

3.  ICD lead type and RV lead position in CRT-D recipients.

Authors:  Alexander P Benz; Mate Vamos; Julia W Erath; Peter Bogyi; Gabor Z Duray; Stefan H Hohnloser
Journal:  Clin Res Cardiol       Date:  2018-05-24       Impact factor: 5.460

4.  Successful support of biventricular heart failure patients by new EXCOR® Adult pumps with bileaflet valves: a prospective study.

Authors:  Bastian Schmack; Alexander Weymann; Frank Ruschitzka; Rüdiger Autschbach; Philip W Raake; Nadine Jurrmann; Ares K Menon; Matthias Karck; Markus J Wilhelm; Arjang Ruhparwar
Journal:  Clin Res Cardiol       Date:  2018-01-02       Impact factor: 5.460

5.  One-year outcomes with the HeartMate 3 left ventricular assist device.

Authors:  Jasmin S Hanke; Günes Dogan; Amelie Zoch; Marcel Ricklefs; Leonhard Wert; Christina Feldmann; Christoph Bara; Malakh Shrestha; Jochen Tillmanns; Tibor Kempf; Johann Bauersachs; Axel Haverich; Jan D Schmitto
Journal:  J Thorac Cardiovasc Surg       Date:  2018-02-13       Impact factor: 5.209

6.  Advanced heart failure treated with continuous-flow left ventricular assist device.

Authors:  Mark S Slaughter; Joseph G Rogers; Carmelo A Milano; Stuart D Russell; John V Conte; David Feldman; Benjamin Sun; Antone J Tatooles; Reynolds M Delgado; James W Long; Thomas C Wozniak; Waqas Ghumman; David J Farrar; O Howard Frazier
Journal:  N Engl J Med       Date:  2009-11-17       Impact factor: 91.245

7.  The HVAD Left Ventricular Assist Device: Risk Factors for Neurological Events and Risk Mitigation Strategies.

Authors:  Jeffrey J Teuteberg; Mark S Slaughter; Joseph G Rogers; Edwin C McGee; Francis D Pagani; Robert Gordon; Eduardo Rame; Michael Acker; Robert L Kormos; Christopher Salerno; Thomas P Schleeter; Daniel J Goldstein; Julia Shin; Randall C Starling; Thomas Wozniak; Adnan S Malik; Scott Silvestry; Gregory A Ewald; Ulrich P Jorde; Yoshifumi Naka; Emma Birks; Kevin B Najarian; David R Hathaway; Keith D Aaronson
Journal:  JACC Heart Fail       Date:  2015-10       Impact factor: 12.035

8.  A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure.

Authors:  Mandeep R Mehra; Yoshifumi Naka; Nir Uriel; Daniel J Goldstein; Joseph C Cleveland; Paolo C Colombo; Mary N Walsh; Carmelo A Milano; Chetan B Patel; Ulrich P Jorde; Francis D Pagani; Keith D Aaronson; David A Dean; Kelly McCants; Akinobu Itoh; Gregory A Ewald; Douglas Horstmanshof; James W Long; Christopher Salerno
Journal:  N Engl J Med       Date:  2016-11-16       Impact factor: 91.245

9.  Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection.

Authors:  Katherine Lietz; James W Long; Abdallah G Kfoury; Mark S Slaughter; Marc A Silver; Carmelo A Milano; Joseph G Rogers; Yoshifumi Naka; Donna Mancini; Leslie W Miller
Journal:  Circulation       Date:  2007-07-16       Impact factor: 29.690

10.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur Heart J       Date:  2016-05-20       Impact factor: 29.983

View more
  2 in total

1.  Optimizing heart failure treatment following cardiac resynchronization therapy.

Authors:  Anders Jorsal; Kasper Pryds; John J V McMurray; Henrik Wiggers; Anders Sommer; Jens Cosedis Nielsen; Roni Ranghøj Nielsen
Journal:  Clin Res Cardiol       Date:  2019-09-26       Impact factor: 5.460

2.  MitraClip implantation followed by insertion of a left ventricular assist device in patients with advanced heart failure.

Authors:  Michael M Kreusser; Sonja Hamed; Andreas Weber; Bastian Schmack; Martin J Volz; Nicolas A Geis; Leonie Grossekettler; Sven T Pleger; Arjang Ruhparwar; Hugo A Katus; Philip W Raake
Journal:  ESC Heart Fail       Date:  2020-10-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.